{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-unidentified-cause/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"be6e1eb9-7eb4-54b8-980d-7a18a90127c3","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 03fe3596-eb95-4261-af38-1d0e810d1d7c --><h2>Changes</h2><!-- end field 03fe3596-eb95-4261-af38-1d0e810d1d7c -->","summary":null,"htmlStringContent":"<!-- begin item dbfefa17-417f-46ea-a417-bfedcf5beb74 --><!-- begin field 752f60a9-f08c-468f-aa7a-6b998ef84b6e --><p><strong>October 2018 </strong>— minor update. Adverse effects updated within prescribing information - metronidazole. </p><p><strong>September 2017 </strong>— minor update. SPC update on quinolones to align all CKS topics prescribing advice. Prostatitis – chronic, Gonorrhoea, Pyelonephritis, Diarrhoea – prevention and advice for travellers, Dyspepsia – unidentified cause, Dyspepsia – proven functional, Dyspepsia – proven peptic ulcer, Diverticular disease, Gastroenteritis. </p><p><strong>April to May 2017 </strong>— reviewed. A literature search was conducted in February 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials since the last revision of this topic. The recommendations on primary care management and referral have been updated in line with the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management </em>(2014). The lower age limit has been changed from 16 to 18 years. The content has been amended to include second-line drug regimens for <em>Helicobacter pylori</em> eradication, in line with the updated NICE guidance. The prescribing information section has been expanded to include antibiotics recommended for <em>H. pylori</em> eradication. The topic has also undergone significant restructuring.</p><!-- end field 752f60a9-f08c-468f-aa7a-6b998ef84b6e --><!-- end item dbfefa17-417f-46ea-a417-bfedcf5beb74 -->","topic":{"id":"f89632d0-8e52-59da-bd63-555a73aa134f","topicId":"ac596995-c452-4bf5-81bf-0aea66eca309","topicName":"Dyspepsia - unidentified cause","slug":"dyspepsia-unidentified-cause","lastRevised":"Last revised in October 2018","chapters":[{"id":"9fdd530d-f12b-5642-954b-6284524a3fdb","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"4ac2b712-5571-56ca-9ac4-25c9e354a821","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"16fcbe75-c057-5b25-8039-9145eb897f12","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"be6e1eb9-7eb4-54b8-980d-7a18a90127c3","slug":"changes","fullItemName":"Changes"},{"id":"8eb7dbc2-40da-5433-b290-44902a364d61","slug":"update","fullItemName":"Update"}]},{"id":"a44ffd66-34ee-565e-8b89-d09f62dd9656","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"ad917944-2a8c-561c-ba7d-5e5c7ea860e4","slug":"goals","fullItemName":"Goals"},{"id":"cbb4bad0-1dbe-5c62-9adc-bb1a65fe6381","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"54d592f8-f244-5cc8-aed5-81cb136af042","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4ca8a0b2-46c5-52c2-a05d-1ae84806cefd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c5e33c66-dee5-57d8-9eff-828ad855e204","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"eff9b41a-cac2-5b9a-8614-2486d8206ffd","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4dfc51d9-1416-5432-bc80-019f5708238c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ec8766af-6b0a-5a4d-8897-2e3ba2af658d","slug":"definition","fullItemName":"Definition"},{"id":"e1cbef45-8ac7-5376-a1d2-c5d0a2cc924b","slug":"causes","fullItemName":"Causes"},{"id":"c7487dda-a4e1-5d9e-bc96-e583302af12c","slug":"prevalence","fullItemName":"Prevalence"}]},{"id":"0eb82dd3-e433-5b8e-a8d9-46987aab8940","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d2acef31-cf6d-5e3e-b2e0-99bc02684183","slug":"assessment","fullItemName":"Assessment"},{"id":"86ebd63c-3596-5ac0-9cd3-4a312bb2d7e4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"f244ecd9-294a-5fa3-9b22-a2e8f2ae408c","fullItemName":"Management","slug":"management","subChapters":[{"id":"bafb1a12-7cf3-5c6c-921a-03d86efd995d","slug":"dyspepsia-unidentified-cause","fullItemName":"Scenario: Dyspepsia - unidentified cause"}]},{"id":"b50160d9-c6d3-5b75-a3a3-9a743c039fb4","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"2978bf31-384a-5964-bba7-5ca72e2a700a","slug":"proton-pump-inhibitors-ppis","fullItemName":"Proton pump inhibitors (PPIs)"},{"id":"a51b3918-0bed-5c45-887b-a5d3e5fd3031","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"},{"id":"8579e41d-876a-5f82-9cb8-04675dce1bb3","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"d41b619e-ef9e-59b6-876b-0b3d52f0884a","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"9ea259a4-6c7f-524f-8866-6164a9696c25","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"640d4b46-3f9c-5cef-aeda-9a374a03fae8","slug":"tetracycline","fullItemName":"Tetracycline"},{"id":"fe5b2b68-8d84-5867-bc39-c63cbcd815f8","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"0857fa25-e261-5ecd-b851-fbe52518072d","slug":"bismuth","fullItemName":"Bismuth"}]},{"id":"210b1a7b-a0e0-558a-acbe-539f538e840d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0e0cffca-8140-5660-bd87-d4288485522f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4726f06d-25b6-56d1-83c0-3d729c2bb571","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"301b4d9b-8d13-5cc1-8e9a-f8f68c4fa019","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5e963a22-e16a-5e4a-b7a9-072decaccaa1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d1d047d4-3011-5ca0-955c-b366ab2a9fb4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"cd5de0cc-ba55-5ad9-b09b-3025cc68334c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cc0ebb19-4869-5b31-8bcf-f0b6e5af54db","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"16fcbe75-c057-5b25-8039-9145eb897f12","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"b095c833-1346-5732-a4eb-5efa6ff8098b","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 20cb50f8-ef87-4dad-a75e-cdabae6cd8df --><h3>Previous changes</h3><!-- end field 20cb50f8-ef87-4dad-a75e-cdabae6cd8df -->","summary":null,"htmlStringContent":"<!-- begin item 237cf390-fe5e-432d-8ea5-7e6bfa2c2942 --><!-- begin field e472e26f-1eb4-49a9-b0a2-c7c3b0af9090 --><p><strong>December 2016</strong> — minor update. minor update. Subacute cutaneous lupus erythematosus has been added as a very infrequent adverse effect of proton pump inhibitors, in line with a Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (2015).</p><p><strong>July 2015 </strong>— minor update. The prescribing information section for clarithromycin has been re-written for clarity.</p><p><strong>February 2015 </strong>— minor update. The prescribing information section was updated to provide additional information regarding the possible drug interaction of clarithromycin with lovastatin or simvastatin in line with the manufacturer's Summary of Product Characteristics (2014).</p><p><strong>May 2014 </strong>— minor update. Domperidone has been removed as a treatment option in line with the European Medicines Agency (EMA) publication <em>PRAC recommends restricting use of domperidone</em> (March 2014).</p><p><strong>August 2013 </strong>— minor update. Metoclopramide has been removed as a treatment option, to reduce the risk of neurological adverse effects, in line with the EMA publication <em>European Medicines Agency recommends changes to the use of metoclopramide</em> (July 2013).</p><p><strong>November 2012 </strong>— reviewed. A literature search was conducted in October 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. There have been minor changes to the recommendation on treatment regimens for <em>Helicobacter pylori </em>eradication failure.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>January 2012 </strong>— minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) in association with the manufacturers have published new safety data regarding the association of domperidone with an increased risk of serious ventricular arrhythmias or sudden cardiac death. This topic has been updated to reflect their advice on dosing, adverse effects, and drug interactions. Issued in February 2012.</p><p><strong>January 2012</strong> —<strong> </strong>minor update. Information from the manufacturer's Summary of Product Characteristics (2011) about the possible drug interaction between pantoprazole and warfarin has been added to the prescribing information section. Information from the British National Formulary (2011) about the potentially serious drug interaction between PPIs and protease inhibitors (atazanavir and saquinavir) has also been added. Issued in January 2012.</p><p><strong>May 2011 </strong>— minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>March 2011 </strong>— topic structure revised to ensure consistency across CKS topics. No changes to clinical recommendations have been made.</p><p><strong>July 2009 </strong>— minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued advice on the interaction between clopidogrel and proton pump inhibitors (2009). Healthcare professionals are advised to avoid concomitant use of these drugs unless considered essential. Issued in July 2009.</p><p><strong>November 2008 </strong>— minor typographical corrections.</p><p><strong>July 2008 </strong>— minor update. The text has been updated to reflect a Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update <em>Nicorandil: risk of gastrointestinal ulceration</em> (June 2008).</p><p><strong>March to June 2008 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There are no major changes to the recommendations.</p><p><strong>May 2007 </strong>— minor update HeliClear triple pack discontinued and prescriptions removed. Issued in May 2007.</p><p><strong>October 2005 </strong>— minor update. HeliMet triple pack discontinued and prescriptions removed. Issued in November 2005.</p><p><strong>July 2005 </strong>— updated to incorporate the <em>Referral guidelines for suspected cancer </em>published by the National Institute for Health and Care Excellence (2005). Issued in July 2005.</p><p><strong>November 2004 </strong>— reviewed and updated to incorporate the National Institute for Health and Care Excellence (NICE) guideline on <em>Dyspepsia </em>(August 2004). Validated in March 2005 and issued in April 2005.</p><p><strong>July 2003 </strong>— updated to incorporate information from the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Dyspepsia </em>(March 2003). Validated in September 2003 and issued in October 2003.</p><p><strong>April 2002 </strong>— updated to include <em>Helicobacter pylori </em>eradication regimens. Issued in April 2002.</p><p><strong>November 2000 </strong>— reviewed and updated to incorporate the Technology appraisal guidance <em>Guidance on the Use of Proton Pump Inhibitors (PPIs) in the Treatment of Dyspepsia</em> issued by the National Institute for Health and Care Excellence (July 2000), and the Department of Health referral guidelines for suspected upper gastrointestinal cancers. Validated in November 2000 and issued in December 2000.</p><p><strong>June 1998 </strong>— new topic, the topic was written.</p><!-- end field e472e26f-1eb4-49a9-b0a2-c7c3b0af9090 --><!-- end item 237cf390-fe5e-432d-8ea5-7e6bfa2c2942 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}